EY singled out two biopharma giants as dominating the supply of firepower—Novo Nordisk and Eli Lilly ... Clayton, NC; Lilly by opening a $2 billion injectable products facility in Concord ...

While the previous funding model punished growth of community colleges, Campbell said, Propel NC proposes ... the area. Eli Lilly, which first broke ground on its state-of-the-art Concord ...

I'm delighted to announce that I will be joining Eli Lilly and Company as a Supply Chain Intern at their Concord, NC location next summer! Grateful to everyone at Eli Lilly who made the ...

Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday at $785.41. Meacham covers the Healthcare sector ...

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price target of $950.00. David Risinger has given his Buy rating ...

I think Eli Lilly and Company's stock correction may be ending as demand for key drugs Zepbound and Mounjaro remains strong, despite recent sales guidance cuts. The company's high valuation ...

Eli Lilly's sales growth is coming short of expectations, which is a problem considering its valuation. The company does have a vast lineup and a deep pipeline that go beyond diabetes and obesity.

During the last three months, 7 analysts shared their evaluations of Eli Lilly LLY, revealing diverse outlooks from bullish to bearish. The table below summarizes their recent ratings, showcasing ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Wall Street expects a year-over-year increase in earnings on higher revenues when Eli Lilly (LLY) reports results for the quarter ended December 2024. While this widely-known consensus outlook is ...